Peter, my concern is the same as the rest of the investment community...a one drug company. The remune deal seemed to offer the potential to offset what will very likely be declining or leveling off of Viracept revenues by sometime next year, but based on it's reception, I'm now questioning that. This drug is reasonably far along in trials and the results just don't seem to have excited the professionals. In the meantime AGPH seems to have committed themselves to huge financial committments. Ms Wong didn't seem to get into that.
With all the new competition in the PI arena, just doesn't seem to me that a growing patient base will offset all the new options available. I'm not clear on the reasons, but the friend of the family with HIV was removed from Viracept earlier in the year, and I believe is taking the latest hot combination that's been biting away at Crixivan.
Admittedly, I do not understand this industry, but I'm not stupid, and the insider selling, sliding stock price, heavy short interest, lack of a warm reception of their latest deals, and apparent zero analyst interest in their pipeline really concern me. Unless there's more information to come tomorrow on Remune, their earth shattering news does not appear to have been well received.
I really appreciate your opinions and input on the thread. I hope you are right...but you have to admit it's a little spooky. You don't hear everyone talking about buying more and averaging down any more either. That got old after 45, then 42, then 40, then 35...
sf |
